Brief: Noxopharm Announces Results From Novel Dual-Cell Therapy Pancreatic Cancer Study
13/09/2022 23:45
Sept 14 (Reuters) - Noxopharm Ltd NOX.AX :
* ANNOUNCES RESULTS FROM NOVEL 'DUAL-CELL' THERAPY
PANCREATIC
CANCER STUDY
* MAJOR FINDINGS WERE THAT CRO-67 KILLED TUMOUR CELLS AS
WELL AS
BARRIER CELLS IN SAMPLES TAKEN FROM SIX PATIENTS
Source text for Eikon: ID:nASX5TZ8jd
Further company coverage: NOX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Noxopharm
See all newsAustralia's Noxopharm hits three-month low on discounted placement
Brief: Noxopharm Receives Commitments For Placement
Brief: Noxopharm Requests Trading Halt Pending Material Capital Raising Announcement
Brief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential